We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,000
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Faecal Incontinence (FI) can have an adverse effect on quality of life. It is a stigmatising condition that may lead to severe social restriction. From the financial point of view, the investigation and treatment of faecal incontinence may add to a significant cost to the health systems of most countries. In fact, the annual treatment cost of patients in the U.K. with urinary and faecal incontinence is of about £500 million.

Many factors may be involved in the pathophysiology of FI. A thorough clinical assessment of the patient is therefore mandatory. This starts with a full history, which may include a cognitive assessment if necessary. The characteristics of the faeces and the type and frequency of incontinence should be noted. Urge incontinence is suggestive of poor external anal sphincter function, whilst passive and post-defaecatory incontinence indicate that internal anal sphincter function is weak. Various questionnaires that enable the clinician to quantify the degree of incontinence and the impact on quality of life are available. These include symptom-specific questionnaires, such as the ones developed by Vaizey et al [1] and Wexner et al [2], the Faecal Incontinence Quality of Life Scale (FIQOL) developed by Rockwood et al [3], and also generic questionnaires such as the Short Form 36 (SF 36) [4].

A full examination of the patient, including the abdomen and perineum, and a neurological examination in some cases, is necessary. Beneficial investigations include a flexible sigmoidoscopy, anal manometry (resting and squeeze pressure), rectal compliance, pudendal nerve terminal motor latency (PNTML) and endoanal ultrasound.

The management of FI is usually multidisciplinary, involving the general practitioner, continence nurse, physiotherapist, gastroenterologist, urologist and colorectal surgeon.
Conservative measures, which include patient education and support, improvement in diet and bowel habit, judicious use of anti-diarrhoeal medication and pelvic floor exercises, are used in the first instance. This is, in fact, recommended in the UK by the National Institute for Clinical Excellence (NICE) guideline ‘CG49 Faecal Incontinence’ [5]. If these measures fail, however, surgical intervention may be necessary. A variety of surgical options are available, with the appropriate therapy being selected depending on the cause of the incontinence and the patient’s cognitive function and general physical condition (Table 1). One of the surgical options available is the use of anal bulking agents.

### Table 1. Surgical Options in the Management of Faecal Incontinence

<table>
<thead>
<tr>
<th>1. Restoration and improvement of residual sphincter function</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Correcting a defective External Anal Sphincter: Sphincteroplasty (End-to-end repair; Overlap repair)</td>
</tr>
<tr>
<td>b. Correcting a defective Pelvic Floor: Levatorplasty</td>
</tr>
<tr>
<td>Postanal Repair</td>
</tr>
<tr>
<td>Total Pelvic Floor Repair</td>
</tr>
<tr>
<td>c. Correction of Anorectal Deformities</td>
</tr>
<tr>
<td>d. Sacral Nerve Stimulation (SNS)</td>
</tr>
<tr>
<td>e. Posterior Tibial Nerve Stimulation (PTNS)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Increasing the outlet resistance of the anal sphincter</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Augmentation of the Anal Sphincter and Anal Cushions (Anal Bulking Agents)</td>
</tr>
<tr>
<td>b. Anal Submucosal Fibrosis (SECCA)</td>
</tr>
<tr>
<td>c. Anal Encirclement (Thiersch procedure)</td>
</tr>
<tr>
<td>d. Non-Dynamic Graciloplasty</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. Dynamic Sphincter Replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Dynamic Graciloplasty</td>
</tr>
<tr>
<td>b. Artificial Anal Sphincter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Antegrade Continence Enema (ACE)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>5. Faecal Diversion</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Colostomy</td>
</tr>
<tr>
<td>b. Ileostomy</td>
</tr>
</tbody>
</table>
2. Anal bulking agents

Anal bulking agents have emerged as a treatment for F.I. following the success of bulking agents for urinary stress incontinence in females. In the urology setting, bulking agents have been employed to augment the bladder neck and increase urethral resistance [6]. Therefore, the aim of anal bulking agents is to prevent F.I. by closing the anal canal or increasing the pressure within the anal sphincter.

The ideal characteristics of a bulking agent have been described in the literature [7]. The injected or implanted substance should be biocompatible, non-migratory, non-allergenic and non-carcinogenic. The substance should also be easy to inject or implant and should produce an improvement in continence, both in the short-term as well as in the long-term.

The evidence for anal bulking agents

Anal injectables and implantables have been used to manage faecal incontinence for over 20 years. It may be useful to chart their development over the years and to classify this development into three phases. The first phase consists of the initial experimental studies that took place in the nineties. The second phase, from about the year 2000 onwards, encompasses an increase in the number of studies using a wide variety of agents and injection techniques. The third phase features the latest generation of anal bulking agents, the implantable THD Gatekeeper.

2.1. Initial studies: The first phase

Anal bulking agents were first described in 1993 by Shafik [8]. Shafik, an Egyptian surgeon, is considered to be a pioneer in this field. In his first study, he described the outcomes following the injection of 5ml of PTFE (Polytef / Teflon) paste in 11 patients, 7 of whom had incontinence following a lateral internal sphincterotomy for anal fissure. In another study, the same author used 60 ml of abdominal wall fat as a submucosal injection into the rectal neck at 3 and 9 o’clock in 14 patients with partial faecal incontinence [9]. Pescatori’s group from Rome, Italy, reported the use of anal injection of autologous buttock fat to restore continence in one patient who had poor results following a sphincteroplasty. This patient’s continence improved following repeated injections [10].

The indications for injection of the anal bulking agents in these studies were various. Most patients had passive FI, but some had urge incontinence, indicating EAS disruption. The results of these initial studies showed that continence was improved in the short term. However, the medium and long-term results were poor, probably because of resorption or migration of the injected material. Re-injection was necessary in order to maintain continence.

A number of safety issues were raised with these studies. Teflon could potentially cause granuloma formation and sarcomas. The injection of autologous fat as a bulking agent in urology has been implicated in fatal fat embolism and stroke.
2.2. The second phase

The second phase in the development of anal bulking agents consisted of a wide variation in the types of materials used, surgical technique and clinical indications [11]. Some of the materials used to bulk the anal sphincter were being used in urology to augment the bladder neck. Nine different types of injectable bulking agents have been used in these studies (Table 2).

<table>
<thead>
<tr>
<th>Type of Bulking agent</th>
<th>Commercial name/s</th>
<th>Injection site</th>
<th>Injection route</th>
<th>Published studies</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silicone biomaterial. Polydimethylsiloxane elastomer particles suspended in a biocompatible hydrogel made of poly-N-vinyl-pyrolidone</td>
<td>PTQ; Bioplastique; within IAS</td>
<td>Intersphincteric</td>
<td>Transsphincteric</td>
<td>21</td>
<td>619</td>
</tr>
<tr>
<td>Carbon-coated zirconium beads, comprised of pyrolytic carbon-coated beads suspended in a water-based carrier gel containing β-glucan</td>
<td>Durasphere</td>
<td>Submucosal</td>
<td>Transsphincteric; Transmucosal</td>
<td>7</td>
<td>187</td>
</tr>
<tr>
<td>Spherical particles of calcium hydroxyapatite, suspended in a gel carrier</td>
<td>Coaptite</td>
<td>Submucosal</td>
<td>Transsphincteric</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Dextranomer microspheres and stabilized sodium hyaluronate in phosphate-buffered 0.9% sodium chloride solution</td>
<td>NASHA Dx, Zuidex, Submucosal; Solesta</td>
<td>Submucosal</td>
<td>Transmucosal</td>
<td>4</td>
<td>56</td>
</tr>
<tr>
<td>Glutaraldehyde cross-linked collagen</td>
<td>Contigen</td>
<td>Submucosal</td>
<td>Transmucosal</td>
<td>2</td>
<td>90</td>
</tr>
<tr>
<td>Synthetic non-particulate hydrogel consisting of water (97.5%) and cross-linked polyacrylamide (2.5%)</td>
<td>Bulkamid</td>
<td>Intersphincteric</td>
<td>Intersphincteric</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Cross-linked porcine dermal collagen matrix</td>
<td>Permacol</td>
<td>Submucosal; Intersphincteric</td>
<td>Transmucosal; Intersphincteric</td>
<td>5</td>
<td>172</td>
</tr>
<tr>
<td>8% Ethylene Vinyl alcohol co-polymer dissolved in dimethyl sulphoxide. A spongy solid mass forms from the solidification of the hydrophobic co-polymer when the solvent diffuses away on contact with tissue fluid</td>
<td>Onyx34</td>
<td>Intershincteric</td>
<td>Intersphincteric</td>
<td>1</td>
<td>21</td>
</tr>
<tr>
<td>Expandable silicone Microballoons filled with a biocompatible hydrogel made of poly-N-vinyl-pyrolidone</td>
<td>Submucosal</td>
<td>Transmucosal</td>
<td></td>
<td>1</td>
<td>6</td>
</tr>
</tbody>
</table>

Table 2. Injectable materials used in the second phase of studies
Indications:
The clinical indications for which these bulking agents were used varied from study to study. These were:

- Failure of conservative management of faecal incontinence
- Structurally intact but weak internal anal sphincter (IAS). This would be due to either primary idiopathic degeneration of the IAS, or degeneration secondary to tissue disorders such as scleroderma
- IAS damage (childbirth, haemorrhoidectomy, anal stretch, sphincterotomy) (Figure 1)
- Defect in the external anal sphincter (EAS)

The main indication was IAS dysfunction or disruption. Unlike the EAS, the IAS is not amenable to surgical repair.

![Figure 1. Endoanal ultrasound scan showing a defect in the IAS of a 57-year-old lady with passive faecal incontinence following haemorrhoidectomy. The defect is present between the arrows from the 3 to the 5 o'clock positions.](image)

Surgical Procedure and Technique:
The bulking agents may be inserted under local, regional (anal or pudendal nerve block) or general anaesthesia. The type of anaesthesia used depends on the preference of the patient and the surgeon. The patient may be positioned in the prone (jack-knife), lithotomy or left lateral positions, although the latter position may not give a satisfactory view of the anorectum to enable accurate injection. A phosphate enema is usually administered preoperatively. The procedure is usually covered by prophylactic antibiotics, such as intravenous (IV) Co-amoxiclav 1.2g, Cefuroxime 750mg and Metronidazole 500mg or Gentamicin 1.5mg/kg and Metronidazole 500mg at induction.
The injection of the bulking agent varies depending on the type of substance used and the clinical indications. Three different routes of needle insertion were mentioned in the literature: transmucosal, trans-sphincteric or intersphincteric. The bulking agent was placed submucosally, within the intersphincteric space or within the IAS itself. For example, porcine dermal collagen (Permacol) may be injected via the transmucosal or trans-sphincteric route using a disposable 19G needle [12] (Figure 2). In patients with an intact IAS, 2.5ml of Permacol is equally injected into the submucosal space at the 3, 7 and 11 o’clock positions above the dentate line. In cases of an IAS defect, 5ml of Permacol may be injected at the site of the defect, with 2.5ml of the substance injected diametrically opposite. With silicone biomaterial (PTQ or Bioplastique), four doses of 2.5ml of silicone are used, using an 18G needle [13, 14]. Patients with an intact IAS have the silicone injected trans-sphincterically into the intersphincteric space at the 2, 4, 8 and 10 o’clock positions. In patients with an IAS defect, for example after a lateral internal sphincterotomy, a total of three doses of 2.5 ml of silicone are injected into the defect. A fourth dose is injected into the intersphincteric space contralateral to the IAS defect, to provide symmetry. With carbon-coated beads (Durasphere) a total of 10ml are injected in four divided doses in the submucosal plane using an 18G needle [14].

It is of utmost importance to ensure that the anal mucosa is not breached during injection, since that would allow intra-anal leakage of the substance. Intravascular injection must also be avoided.

Once the injection is completed, it is good practice to leave the needle and syringe in place for a few seconds. As the needle is being withdrawn, pressure on the needle track by the index finger may prevent leakage of the bulking agent [12].

The bulking agent may be injected freehand, with an anal retractor such as Eisenhammer used to identify the IAS and intersphincteric groove. A finger placed within the anal canal may be useful to guide the needle to its correct position. However endoanal ultrasound has been recommended to guide the needle to an optimum position [13], especially if the agent is to be injected into the intersphincteric space or adjacent to a defect in the IAS.
Results:

The majority of studies in this second phase of development were mainly case series and observational studies. Most of these studies reported either an improvement in the faecal continence scores or less frequent episodes of incontinence over time. Anorectal manometry testing featured in some studies, with some showing an improvement in resting or squeeze pressures. Others studies showed no such improvement. Clinical improvement was not always associated with an increase in these pressures. Quality of life was formally assessed in some of these studies. The majority reported an improvement across various domains such as physical and social function.

To date there have been five randomised trials using anal bulking agents, with a total of 382 patients. Two trials compared a bulking agent with a sham or saline injection. Siproudhis et al in 2007 [15] compared a silicone biomaterial (PTQ) with a normal saline injection (control) into the intersphincteric space. PTQ did not demonstrate any appreciable clinical benefit when compared to the control. The trial was however deemed to be too small to detect any differences in continence. Graf et al in 2011[16] compared the injection of dextranomer (NASHADx) against sham injection (no substance injected). Continence was better in the short term (6 months) in the active intervention group, although interestingly about 30% of patients in the control group had an improvement in their continence.

A small study with ten patients by Maeda et al in 2008 [17] revealed significant improvement at 6 weeks post injection using injection of Bulkamid and Permacol. Continence decreased slightly in the Permacol group at 6 months. However there was no reported difference between the two agents. The numbers were too small to detect a difference. Tjandra et al in 2009, reported the results of a randomised study comparing PTQ with carbon-coated beads (Dura‐sphere) [14]. PTQ injection was associated with better continence scores and quality of life, and was safer, than Durasphere.

Tjandra et al in 2004 reported the short-term benefits from ultrasound guided injection of silicone biomaterial (PTQ) compared with digital guidance [13].

The follow up for the majority of patients in studies was less than a median of 3 years. A question on the term durability and effectiveness of these agents is therefore raised. The majority (97%) of patients were only followed up once or twice. No long-term evidence on outcomes was available and further conclusions were not warranted from the available data. None of the studies reported patient evaluation of outcomes and thus it is difficult to gauge whether the improvement in the continence scores matched the practical symptom and quality of life improvements that mattered to the patients.

The majority of patients did not report any complications. The complications described were mainly pain, anal bruising and leakage of injected material [11, 12]. Less common complications were anal ulceration and infection (local cellulitis and abscess formation). There were two reported cases of local giant cell foreign body reaction after injection of silicone (PTQ)[18]. Durasphere has been associated with skin rashes and arthritis. Skin patch testing is therefore recommended before using this agent [14].
2.3. The third phase: The implantable THD Gatekeeper

A relatively new and innovative development in anal bulking technology is the THD Gatekeeper (THD S.p.A., Correggio, Italy). The material used is Polyacrylonitrile or Hyexpan. It is an inert, non-allergenic, non-degradable material that is also non-immunogenic, and non-carcinogenic. First developed by Medtronic in Minneapolis, USA, it was originally used as an implant in the oesophagogastric junction for the management of gastro-oesophageal reflux disease.

The main indications for the use of the THD Gatekeeper are passive faecal incontinence, secondary to IAS dysfunction or damage, where conservative measures or injection of other bulking agents such as PTQ or Permacol have failed.

The following are contraindications to the use of the Gatekeeper. Similar contraindications have also been described by the product manufacturers of other anal bulking agents.

- Perianal sepsis
- Inflammatory bowel diseases with anorectal involvement (Crohn’s disease, ulcerative colitis)
- Anal cancer
- Rectal or colon cancer undergoing active treatment;
- Rectal bleeding of unknown or undiagnosed origin;
- Rectal prolapse
- Uncontrolled blood coagulation disorders
- Pelvic radiotherapy
- Immunosuppression
- Pregnancy or planned pregnancy in the next 12 months.

Surgical Apparatus, Procedure and Technique:

Whereas the anal bulking agents that were developed in phases 1 and 2 are injected into or around the anal canal by means of a hypodermic syringe, the Hyexpan prostheses are implanted into the intersphincteric space using a custom-made gun (Figure 3).

The prostheses consist of thin solid cylinders, 22mm long and 2mm in diameter. The success of this material depends on its hydrophilic properties. Within 24 hours after implantation in human tissue, the Hyexpan cylinders absorb water to become thicker and shorter. The in vitro maximum diameter is 6.5 mm and the length is 17 mm (Figure 4). The volume of each individual implant increases from approximately $70\text{mm}^3$ to $500\text{mm}^3$, a 750% increase. The implant is also much softer in consistency compared to the firm consistency prior to implantation.
The operation is performed under regional or general anesthesia. Intravenous antibiotics are given at induction. The author’s patients receive Gentamicin 1.5 mg/kg and Metronidazole 500mg IV. The patient is placed in the lithotomy position. A strict sterile technique is used. The IAS and intersphincteric groove are identified by the placement of an anal retractor (eg. Eisenhammer or Park’s). The author’s preference is a THD surgy Mini-light proctoscope, a self illuminating anal and rectal retractor that gives a very good view of the anorectum without causing trauma to the anal sphincter (Figure 5).
Figure 5. Palpating the IAS and the intersphincteric groove at the 6 o’clock position with a THD surgy Mini-light proctoscope in position.

A 2mm incision is made in the perianal skin, 2 cm from the anal verge (Figure 6).

Figure 6. Making an incision, 2cm away from the anal verge, at the 6 o’clock position.

Having attached the dispenser to the delivery system, the needle is inserted through the incision and tunneled to the intersphincteric margin and introduced into the intersphincteric space. The needle is then positioned so that the tip would lie just beyond the dentate line. When the needle is identified in the correct position, by direct vision and palpation and/or by endoanal ultrasound, the prosthesis is released into the intersphincteric space (Figure 7).
The steps may be repeated to insert between four to six prostheses, equidistant from each other. The choice of inserting 4 as opposed to 6 prostheses is arbitrary. The wounds are closed with a single absorbable suture (Figure 8). At the end of procedure, EAUS imaging will show the location of all prostheses.

Figure 7. THD Gatekeeper needle at the 9 o’clock position, with the endoanal ultrasound probe in place to determine correct placement.

Figure 8. Six equidistant circumferential perianal wounds each closed with an absorbable suture (Monocryl 3/0).
The procedure takes about 30 to 40 minutes to complete, and is done as a day-case. Oral metronidazole 400mg tds is prescribed for 5 days postoperatively. Oral laxatives such as lactulose are prescribed to minimize the risk of constipation. The patients are advised to avoid any anal trauma as well as anal intercourse for at least 72 h after implant insertion.

The patients are followed up after 6 weeks and 3 monthly thereafter.

The material remains identifiable both by palpation and by endoanal ultrasonography in the postoperative period (Figure 9).

Figure 9. Endoanal ultrasound scan at 6 weeks following the implantation of four Gatekeeper prostheses (arrows) in a 72 year old male with idiopathic passive faecal incontinence.

Results:

The first reported experience with the THD Gatekeeper was by Ratto et al in 2011 [19]. This was a study with 14 patients. Eight had idiopathic FI, 4 had an IAS defect and 2 had combined IAS and EAS defects. The median follow-up was of 12 months (range 5 to 48 months). The authors reported a clinically significant improvement in continence in 13 patients, a sustained significant improvement in the Wexner and Vaizey scores and in the SF36 and FIQL quality of life scores. No complications have been reported.

The second study was a comparative retrospective study by Parello et al in 2012 [20]. Seven patients who had the THD Gatekeeper implanted were compared to 6 patients who underwent
sacral nerve stimulation (SNS). The median follow up was of 18 months in the Gatekeeper group and 20 months in the SNS group. The authors reported a sustained improvement in the Wexner continence scores with both modalities of treatment.

The results of the author’s first 5 patients using this novel technique were evaluated. One was male and 4 were female. Four had idiopathic FI and one had passive incontinence following anal stretch for anal fissure. All patients had failed conservative management. There was a significant improvement in median Vaizey scores at 6 months (16 vs 4, p<0.01). One patient, who was assessed at 12 months, had a sustained score improvement from 14 at baseline to 3 at 3, 6 and 12 months. There have not been any complications to date.

3. Discussion

The development of anal injectable and implantable technology over the past 20 years has taken great strides forwards. Starting with the pioneering efforts of Shafik with autologous fat, more materials have been tried and used, the more popular being Collagen (Permacol) and Silicone (PTQ or Bioplastique). These agents were associated with variable and inconsistent results. Injections were frequently repeated to maintain continence long term. The latest generation of anal bulking agents is the implantable Hyexpan (THD Gatekeeper). This material fits the criteria for the ‘ideal’ bulking agent. It overcomes most limitations of other bulking agents, and its use has shown very promising initial results. Whether these results are maintained in the longer term or not awaits to be seen.

The mechanism of action of anal bulking agents is a subject of debate. Most of the resting anal pressure is the function of the IAS, with some contribution from the EAS and anal cushions. Studies of faecal incontinence in patients who have undergone a traditional Milligan Morgan haemorrhoidectomy lend support the concept that anal cushions play an important part in the maintenance of the normal mechanism of continence. It is thought that the mechanism of action of a bulking agent injected into the submucosal space is an increase in the size of the natural anal cushions. On the other hand, a bulking agent injected or implanted into the intersphincteric space would bulk the size of the anal sphincter. The end result would be an improvement in the seal of the lumen of the anal canal at rest and potentially an increase in resting anal pressure and in the length of the anal high pressure zone. When the injection is placed adjacent to an identifiable IAS defect, a better degree of anal canal sealing may be obtained through improvement in the configuration and symmetry of the anal canal [7].

It is acknowledged that more research required in this field. Most studies are case series with very few randomised trials.

Larger series with longer follow up and randomised controlled trials are therefore necessary. Further development on existing and emerging technology is also warranted.
Author details

John Camilleri-Brennan1,2*

Address all correspondence to: johncbrennan@doctors.org.uk

1 Department of Surgery, Forth Valley Royal Hospital, Larbert, Stirlingshire, Scotland
2 University of Glasgow Medical School, Glasgow, Scotland

References


